- Home
- LTC vs IRON Comparison
LTC vs IRON Comparison
Compare LTC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- IRON
- Stock Information
- Founded
- LTC 1992
- IRON 2017
- Country
- LTC United States
- IRON United States
- Employees
- LTC N/A
- IRON N/A
- Industry
- LTC Real Estate Investment Trusts
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- LTC Real Estate
- IRON Health Care
- Exchange
- LTC Nasdaq
- IRON Nasdaq
- Market Cap
- LTC 1.6B
- IRON 1.4B
- IPO Year
- LTC 1992
- IRON N/A
- Fundamental
- Price
- LTC $34.98
- IRON $51.61
- Analyst Decision
- LTC Hold
- IRON Strong Buy
- Analyst Count
- LTC 5
- IRON 10
- Target Price
- LTC $37.80
- IRON $93.40
- AVG Volume (30 Days)
- LTC 293.8K
- IRON 372.4K
- Earning Date
- LTC 07-28-2025
- IRON 08-07-2025
- Dividend Yield
- LTC 6.51%
- IRON N/A
- EPS Growth
- LTC 0.36
- IRON N/A
- EPS
- LTC 1.93
- IRON N/A
- Revenue
- LTC $202,686,000.00
- IRON N/A
- Revenue This Year
- LTC N/A
- IRON N/A
- Revenue Next Year
- LTC $11.33
- IRON N/A
- P/E Ratio
- LTC $18.12
- IRON N/A
- Revenue Growth
- LTC 3.98
- IRON N/A
- 52 Week Low
- LTC $31.70
- IRON $30.82
- 52 Week High
- LTC $39.89
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- LTC 46.60
- IRON 56.99
- Support Level
- LTC $34.62
- IRON $48.87
- Resistance Level
- LTC $35.44
- IRON $54.13
- Average True Range (ATR)
- LTC 0.57
- IRON 2.31
- MACD
- LTC -0.01
- IRON 0.07
- Stochastic Oscillator
- LTC 36.59
- IRON 67.64
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.